{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:01:51Z","timestamp":1784628111128,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Science Foundation for Young Scientists of China","award":["8150020951"],"award-info":[{"award-number":["8150020951"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10557-026-07834-1","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:18:24Z","timestamp":1768205904000},"page":"1457-1472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin Supplementation in Cardioplegic Solution Improves Donor Heart Preservation by Maintaining Mitochondrial Homeostasis"],"prefix":"10.1007","volume":"40","author":[{"given":"Rui-lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Chun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Lu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-4214","authenticated-orcid":false,"given":"Yi-feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"2","key":"7834_CR1","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2018.11","volume":"2018","author":"DKC Cooper","year":"2018","unstructured":"Cooper DKC. Christiaan Barnard-the surgeon who dared: the story of the first human-to-human heart transplant. Glob Cardiol Sci Pract. 2018;(2):11. https:\/\/doi.org\/10.21542\/gcsp.2018.11.","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"7834_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2023.104191","volume":"53","author":"K Bounader","year":"2024","unstructured":"Bounader K, Flecher E. End-stage heart failure: the future of heart transplant and artificial heart. Presse Med. 2024;53(1):104191. https:\/\/doi.org\/10.1016\/j.lpm.2023.104191.","journal-title":"Presse Med"},{"issue":"10","key":"7834_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.healun.2021.07.015","volume":"40","author":"KK Khush","year":"2021","unstructured":"Khush KK, Hsich E, Potena L, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report \u2212 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1035\u201349. https:\/\/doi.org\/10.1016\/j.healun.2021.07.015.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"7834_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-025-11323-4","volume":"26","author":"RL Liu","year":"2025","unstructured":"Liu RL, Yang YF, Gong K, et al. Whole exome sequence reveals genetic profiles of primary cardiomyopathy and genotype-phenotype association in Chinese population. BMC Genomics. 2025;26(1):150. https:\/\/doi.org\/10.1186\/s12864-025-11323-4.","journal-title":"BMC Genomics"},{"issue":"10","key":"7834_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail. 2021;14(10):e008406. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008406.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"7834_CR6","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/TP.0000000000005185","volume":"109","author":"JR Paez","year":"2025","unstructured":"Paez JR, White RE, Dunn K, et al. Investigating cardiac temperature during heart transplantation using the static cold storage paradigm. Transplantation. 2025;109(3):e148\u201356. https:\/\/doi.org\/10.1097\/TP.0000000000005185.","journal-title":"Transplantation"},{"issue":"5","key":"7834_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/icvts\/ivab164","volume":"33","author":"A Pannekoek","year":"2021","unstructured":"Pannekoek A, Ali U. Does the solution used for cold static storage of hearts impact on heart transplant survival? Interact Cardiovasc Thorac Surg. 2021;33(5):814\u20138. https:\/\/doi.org\/10.1093\/icvts\/ivab164.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"10","key":"7834_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018;78(10):1037\u201348. https:\/\/doi.org\/10.1007\/s40265-018-0937-z.","journal-title":"Drugs"},{"issue":"1","key":"7834_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10557-023-07517-1","volume":"39","author":"M Ryaboshapkina","year":"2025","unstructured":"Ryaboshapkina M, Ye R, Ye Y, Birnbaum Y. Effects of dapagliflozin on myocardial gene expression in BTBR mice with type 2 diabetes. Cardiovasc Drugs Ther. 2025;39(1):43\u201361. https:\/\/doi.org\/10.1007\/s10557-023-07517-1.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7834_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10557-024-07594-w","volume":"39","author":"N Hadebe","year":"2025","unstructured":"Hadebe N, Cour M, Imamdin A, et al. Cardioprotection with intralipid during coronary artery bypass grafting surgery on cardiopulmonary bypass: a randomized clinical trial. Cardiovasc Drugs Ther. 2025;39(5):1045. https:\/\/doi.org\/10.1007\/s10557-024-07594-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"21","key":"7834_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","volume":"149","author":"AF Hernandez","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, et al. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024;149(21):1627. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069217.","journal-title":"Circulation"},{"issue":"15","key":"7834_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"22","key":"7834_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"5","key":"7834_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s10557-024-07593-x","volume":"39","author":"F Polat","year":"2025","unstructured":"Polat F, Kaya Z, Suleymanoglu C. Comparative analysis of the addition of empagliflozin versus doubling the furosemide dose in decompensated heart failure. Cardiovasc Drugs Ther. 2025;39(5):1033\u201343. https:\/\/doi.org\/10.1007\/s10557-024-07593-x.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"7834_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01532-6","volume":"21","author":"R Zou","year":"2022","unstructured":"Zou R, Shi W, Qiu J, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion injury through improving mitochondrial homeostasis. Cardiovasc Diabetol. 2022;21(1):106. https:\/\/doi.org\/10.1186\/s12933-022-01532-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7834_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24103-x","volume":"12","author":"Q Wang","year":"2022","unstructured":"Wang Q, Ju F, Li J, et al. Empagliflozin protects against renal ischemia\/reperfusion injury in mice. Sci Rep. 2022;12(1):19323. https:\/\/doi.org\/10.1038\/s41598-022-24103-x.","journal-title":"Sci Rep"},{"issue":"3","key":"7834_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/jpet.121.000956","volume":"380","author":"D Huang","year":"2022","unstructured":"Huang D, Ju F, Du L, et al. Empagliflozin protects against pulmonary ischemia\/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J Pharmacol Exp Ther. 2022;380(3):230\u201341. https:\/\/doi.org\/10.1124\/jpet.121.000956.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"7834_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","volume":"43","author":"RG Abdel-Latif","year":"2020","unstructured":"Abdel-Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1alpha\/VEGF signaling pathway. Arch Pharm Res. 2020;43(5):514\u201325. https:\/\/doi.org\/10.1007\/s12272-020-01237-y.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"7834_CR19","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","volume":"10","author":"DK Patel","year":"2019","unstructured":"Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10(5):1771\u201392. https:\/\/doi.org\/10.1007\/s13300-019-00686-z.","journal-title":"Diabetes Ther"},{"issue":"18","key":"7834_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732.","journal-title":"Circulation"},{"key":"7834_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.103010","volume":"69","author":"W Cai","year":"2024","unstructured":"Cai W, Chong K, Huang Y, Huang C, Yin L. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol. 2024;69:103010. https:\/\/doi.org\/10.1016\/j.redox.2023.103010.","journal-title":"Redox Biol"},{"issue":"8","key":"7834_CR22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19586.","journal-title":"Hypertension"},{"issue":"4","key":"7834_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10557-023-07434-3","volume":"38","author":"JH Amesz","year":"2024","unstructured":"Amesz JH, Langmuur SJJ, Epskamp N, et al. Acute biomechanical effects of empagliflozin on living isolated human heart failure myocardium. Cardiovasc Drugs Ther. 2024;38(4):659\u201366. https:\/\/doi.org\/10.1007\/s10557-023-07434-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7834_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41418-022-01094-w","volume":"30","author":"E Vringer","year":"2023","unstructured":"Vringer E, Tait SWG. Mitochondria and cell death-associated inflammation. Cell Death Differ. 2023;30(2):304\u201312. https:\/\/doi.org\/10.1038\/s41418-022-01094-w.","journal-title":"Cell Death Differ"},{"key":"7834_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07642-5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang H, Yan B, et al. Ferroptosis in cardiovascular diseases and ferroptosis-related intervention approaches. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07642-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7834_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10557-024-07582-0","volume":"38","author":"WD Watson","year":"2024","unstructured":"Watson WD, Arvidsson PM, Miller JJJ, Lewis AJ, Rider OJ. A mitochondrial basis for heart failure progression. Cardiovasc Drugs Ther. 2024;38(6):1161\u201371. https:\/\/doi.org\/10.1007\/s10557-024-07582-0.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7834_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, et al. <article-title update=\"added\">Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022;52:102288. https:\/\/doi.org\/10.1016\/j.redox.2022.102288.","journal-title":"Redox Biol"},{"issue":"1","key":"7834_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-023-00457-6","volume":"28","author":"W Yang","year":"2023","unstructured":"Yang W, Li X, He L, et al. Empagliflozin improves renal ischemia-reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK-OPA1 pathway promotion. Cell Mol Biol Lett. 2023;28(1):42. https:\/\/doi.org\/10.1186\/s11658-023-00457-6.","journal-title":"Cell Mol Biol Lett"},{"key":"7834_CR29","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212264","volume":"3","author":"EM Vivian","year":"2014","unstructured":"Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014;3:212264. https:\/\/doi.org\/10.7573\/dic.212264.","journal-title":"Drugs Context"},{"key":"7834_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004007.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"7834_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jchf.2023.11.015","volume":"12","author":"JN Schroder","year":"2024","unstructured":"Schroder JN, Patel CB, DeVore AD, et al. Increasing utilization of extended criteria donor hearts for transplantation: the OCS heart EXPAND trial. JACC Heart Fail. 2024;12(3):438\u201347. https:\/\/doi.org\/10.1016\/j.jchf.2023.11.015.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"7834_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/icvts\/ivu432","volume":"20","author":"SM Minasian","year":"2015","unstructured":"Minasian SM, Galagudza MM, Dmitriev YV, Karpov AA, Vlasov TD. Preservation of the donor heart: from basic science to clinical studies. Interact Cardiovasc Thorac Surg. 2015;20(4):510\u20139. https:\/\/doi.org\/10.1093\/icvts\/ivu432.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"9","key":"7834_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/lt.26528","volume":"28","author":"DP Foley","year":"2022","unstructured":"Foley DP. Comparing preservation solutions for static cold storage in donation after circulatory death liver transplantation. Liver Transpl. 2022;28(9):1423\u20134. https:\/\/doi.org\/10.1002\/lt.26528.","journal-title":"Liver Transpl"},{"issue":"11","key":"7834_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/LVT.0000000000000162","volume":"29","author":"DD Lee","year":"2023","unstructured":"Lee DD, Joyce C, Duehren S, Fernandez L. Oxygen saturation during donor warm ischemia time and outcome of donation after circulatory death (DCD) liver transplantation with static cold storage: a review of 1114 cases. Liver Transpl. 2023;29(11):1192\u20138. https:\/\/doi.org\/10.1097\/LVT.0000000000000162.","journal-title":"Liver Transpl"},{"issue":"7703","key":"7834_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41586-018-0047-9","volume":"557","author":"D Nasralla","year":"2018","unstructured":"Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0047-9.","journal-title":"Nature"},{"issue":"6","key":"7834_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.healun.2023.01.014","volume":"42","author":"N Moeslund","year":"2023","unstructured":"Moeslund N, Ertugrul IA, Hu MA, et al. Ex-situ oxygenated hypothermic machine perfusion in donation after circulatory death heart transplantation following either direct procurement or in-situ normothermic regional perfusion. J Heart Lung Transplant. 2023;42(6):730\u201340. https:\/\/doi.org\/10.1016\/j.healun.2023.01.014.","journal-title":"J Heart Lung Transplant"},{"issue":"10453","key":"7834_CR37","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S0140-6736(24)01078-X","volume":"404","author":"F Rega","year":"2024","unstructured":"Rega F, Lebreton G, Para M, et al. Hypothermic oxygenated perfusion of the donor heart in heart transplantation: the short-term outcome from a randomised, controlled, open-label, multicentre clinical trial. Lancet. 2024;404(10453):670\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(24)01078-X.","journal-title":"Lancet"},{"key":"7834_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10258","volume":"35","author":"G Qin","year":"2022","unstructured":"Qin G, Jernryd V, Sjoberg T, Steen S, Nilsson J. Machine perfusion for human heart preservation: a systematic review. Transpl Int. 2022;35:10258. https:\/\/doi.org\/10.3389\/ti.2022.10258.","journal-title":"Transpl Int"},{"issue":"6","key":"7834_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s12265-022-10246-9","volume":"15","author":"H Yang","year":"2022","unstructured":"Yang H, Zhou P, Li Q, et al. TJ-M2010-5 attenuates severe myocardial ischemia\/reperfusion injury in heart transplantation by inhibiting MyD88 homodimerization in vivo. J Cardiovasc Transl Res. 2022;15(6):1366\u201376. https:\/\/doi.org\/10.1007\/s12265-022-10246-9.","journal-title":"J Cardiovasc Transl Res"},{"issue":"11","key":"7834_CR40","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/ajt.15539","volume":"19","author":"C Zhu","year":"2019","unstructured":"Zhu C, Su Y, Juriasingani S, et al. Supplementing preservation solution with mitochondria-targeted H(2) S donor AP39 protects cardiac grafts from prolonged cold ischemia-reperfusion injury in heart transplantation. Am J Transplant. 2019;19(11):3139\u201348. https:\/\/doi.org\/10.1111\/ajt.15539.","journal-title":"Am J Transplant"},{"issue":"12","key":"7834_CR41","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1161\/CIRCULATIONAHA.108.787390","volume":"120","author":"X Zheng","year":"2009","unstructured":"Zheng X, Lian D, Wong A, et al. Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation. 2009;120(12):1099\u2013107. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.787390.","journal-title":"Circulation"},{"issue":"3","key":"7834_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1159\/000487295","volume":"45","author":"G Liu","year":"2018","unstructured":"Liu G, Zhang H, Hao F, et al. Clusterin reduces cold ischemia-reperfusion injury in heart transplantation through regulation of NF-kB signaling and Bax\/Bcl-xL expression. Cell Physiol Biochem. 2018;45(3):1003\u201312. https:\/\/doi.org\/10.1159\/000487295.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"7834_CR43","first-page":"281","volume":"11","author":"H Jing","year":"2018","unstructured":"Jing H, Zou G, Hao F, Wang H, Wang S. Hsp27 reduces cold ischemia-reperfusion injury in heart transplantation through regulation of NF-kappaB and PUMA signaling. Int J Clin Exp Pathol. 2018;11(1):281\u201392.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"7834_CR44","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"issue":"2","key":"7834_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137(2):119\u201329. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028268.","journal-title":"Circulation"},{"key":"7834_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ebiom.2018.01.025","volume":"28","author":"H Zhao","year":"2018","unstructured":"Zhao H, Alam A, Soo AP, George AJT, Ma D. Ischemia-reperfusion injury reduces long term renal graft survival: mechanism and beyond. EBioMedicine. 2018;28:31\u201342. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.025.","journal-title":"EBioMedicine"},{"issue":"1","key":"7834_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/ajt.16149","volume":"21","author":"IKA Jones","year":"2021","unstructured":"Jones IKA, Orloff S, Burg JM, et al. Blocking the IL-1 receptor reduces cardiac transplant ischemia and reperfusion injury and mitigates CMV-accelerated chronic rejection. Am J Transplant. 2021;21(1):44\u201359. https:\/\/doi.org\/10.1111\/ajt.16149.","journal-title":"Am J Transplant"},{"issue":"5","key":"7834_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/ajt.12672","volume":"14","author":"SO Syrjala","year":"2014","unstructured":"Syrjala SO, Tuuminen R, Nykanen AI, et al. Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am J Transplant. 2014;14(5):1096\u2013108. https:\/\/doi.org\/10.1111\/ajt.12672.","journal-title":"Am J Transplant"},{"issue":"10","key":"7834_CR49","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","volume":"36","author":"W Liu","year":"2024","unstructured":"Liu W, You D, Lin J, et al. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation. Cell Metab. 2024;36(10):2245. 61 e6.","journal-title":"Cell Metab"},{"issue":"8","key":"7834_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07015-8","volume":"15","author":"S Tang","year":"2024","unstructured":"Tang S, Fuss A, Fattahi Z, Culmsee C. Drp1 depletion protects against ferroptotic cell death by preserving mitochondrial integrity and redox homeostasis. Cell Death Dis. 2024;15(8):626. https:\/\/doi.org\/10.1038\/s41419-024-07015-8.","journal-title":"Cell Death Dis"},{"key":"7834_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00732","volume":"8","author":"W Chen","year":"2020","unstructured":"Chen W, Li D. Reactive oxygen species (ROS)-responsive nanomedicine for solving ischemia-reperfusion injury. Front Chem. 2020;8:732. https:\/\/doi.org\/10.3389\/fchem.2020.00732.","journal-title":"Front Chem"},{"issue":"1","key":"7834_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yexcr.2018.04.025","volume":"369","author":"N Li","year":"2018","unstructured":"Li N, Wang H, Jiang C, Zhang M. Renal ischemia\/reperfusion-induced mitophagy protects against renal dysfunction via Drp1-dependent-pathway. Exp Cell Res. 2018;369(1):27\u201333. https:\/\/doi.org\/10.1016\/j.yexcr.2018.04.025.","journal-title":"Exp Cell Res"},{"key":"7834_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101415","volume":"30","author":"J Wang","year":"2020","unstructured":"Wang J, Zhu P, Li R, Ren J, Zhou H. Fundc1-dependent mitophagy is obligatory to ischemic preconditioning-conferred renoprotection in ischemic AKI via suppression of Drp1-mediated mitochondrial fission. Redox Biol. 2020;30:101415. https:\/\/doi.org\/10.1016\/j.redox.2019.101415.","journal-title":"Redox Biol"},{"issue":"5\u20136","key":"7834_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/iep.12336","volume":"100","author":"J Gao","year":"2019","unstructured":"Gao J, Wang H, Li Y, Li W. Resveratrol attenuates cerebral ischaemia reperfusion injury via modulating mitochondrial dynamics homeostasis and activating AMPK-Mfn1 pathway. Int J Exp Pathol. 2019;100(5\u20136):337\u201349. https:\/\/doi.org\/10.1111\/iep.12336.","journal-title":"Int J Exp Pathol"},{"key":"7834_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060920","author":"NA Vilchinskaya","year":"2023","unstructured":"Vilchinskaya NA, Rozhkov SV, Turtikova OV, Mirzoev TM, Shenkman BS. AMPK phosphorylation impacts apoptosis in differentiating myoblasts isolated from atrophied rat soleus muscle. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12060920.","journal-title":"Cells"},{"key":"7834_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1126391","volume":"10","author":"L Xu","year":"2023","unstructured":"Xu L, Zeng Z, Niu C, et al. Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation. Front Cardiovasc Med. 2023;10:1126391. https:\/\/doi.org\/10.3389\/fcvm.2023.1126391.","journal-title":"Front Cardiovasc Med"},{"key":"7834_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.733183","volume":"9","author":"J Lu","year":"2021","unstructured":"Lu J, Xu L, Zeng Z, et al. Normothermic ex vivo heart perfusion combined with melatonin enhances myocardial protection in rat donation after circulatory death hearts via inhibiting NLRP3 inflammasome-mediated pyroptosis. Front Cell Dev Biol. 2021;9:733183. https:\/\/doi.org\/10.3389\/fcell.2021.733183.","journal-title":"Front Cell Dev Biol"},{"key":"7834_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107001","volume":"145","author":"G Alloatti","year":"2022","unstructured":"Alloatti G, Penna C, Comita S, et al. Aging, sex and NLRP3 inflammasome in cardiac ischaemic disease. Vascul Pharmacol. 2022;145:107001. https:\/\/doi.org\/10.1016\/j.vph.2022.107001.","journal-title":"Vascul Pharmacol"},{"issue":"2","key":"7834_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121\u201335. https:\/\/doi.org\/10.1038\/nrm.2017.95.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7834_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1290046","volume":"11","author":"AE Atici","year":"2023","unstructured":"Atici AE, Crother TR, Noval Rivas M. Mitochondrial quality control in health and cardiovascular diseases. Front Cell Dev Biol. 2023;11:1290046. https:\/\/doi.org\/10.3389\/fcell.2023.1290046.","journal-title":"Front Cell Dev Biol"},{"key":"7834_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120070","volume":"286","author":"AM Abdelhamid","year":"2021","unstructured":"Abdelhamid AM, Youssef ME, Abd El-Fattah EE, et al. <article-title update=\"added\">Blunting p38 MAPK\u03b1 and ERK1\/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-\u03baB inactivation in mice intoxicated with carbon tetrachloride. Life Sci. 2021;286:120070. https:\/\/doi.org\/10.1016\/j.lfs.2021.120070.","journal-title":"Life Sci"},{"issue":"6","key":"7834_CR62","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/phar.1396","volume":"34","author":"PM Reynolds","year":"2014","unstructured":"Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617\u201332. https:\/\/doi.org\/10.1002\/phar.1396.","journal-title":"Pharmacotherapy"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07834-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:36Z","timestamp":1784624856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07834-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7834"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07834-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of The Second Xiangya Hospital, Central South University (Approval No. XYDW20240030), and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}